Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Use of Dipeptidyl peptidase-4 inhibitors is associated with lower risk of dementia in diabetic patients

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: LIN, Yi-Ting (Kaohsiung Municipal Siaogang Hospital, Department of Family Medicine, Kaohsiung, China Taiwan)
  • Co-author(s): Yi-Ting Lin: Department of Family Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan, Province of China;Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Province of China;Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
    Ping-Hsun Wu: Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Province of China;Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
    Yi-Hsin Yang: School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
    Yuan-Han Yang: Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan, Province of China;Department of and Master’s Program in Neurology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China
  • Abstract:

    Backgrounds

    Diabetes mellitus is associated with increased risk of dementia. Recent studies have shown that antidiabetic drugs have brain protection effect. However, rare study investigates the effect of Dipeptidyl peptidase-4 (DPP-4) inhibitors on dementia risk in patients with Diabetes Mellitus (DM).

    Aims

    To evaluate the association between the

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses